

We Claim:

1. A method of treating a patient suffering from sepsis which comprises, administering to said patient a pharmaceutically effective amount of protein C in combination with bactericidal/permeability-increasing (BPI) protein.

2. The method of Claim 1, wherein said patient is human.

3. The method of Claim 1 wherein the protein C is human protein C zymogen.

4. The method of Claim 1 wherein the protein C is human activated protein C.

5. The method according to Claim 4, wherein the amount of human activated protein C is about 1 $\mu\text{g/kg/hr}$ to about 50 $\mu\text{g/kg/hr}$.

6. The method of Claim 5, wherein the human activated protein C is administered by continuous infusion for about 1 to about 240 hours.

7. The method of Claim 1, wherein the BPI protein is administered by bolus injection.

8. The method of Claim 7, wherein the amount of BPI protein is about 0.1 mg/kg to about 10 mg/kg of body weight.

9. The method of Claim 1, wherein the BPI protein is administered by continuous infusion for about 1 to about 240 hours.

10. The method of Claim 9, wherein the amount of BPI protein is about 4 $\mu\text{g/kg/hr}$ to about 420 $\mu\text{g/kg/hr}$.

11. A method of treating sepsis in a patient in need thereof, which comprises administering to said patient a pharmaceutically effective amount of BPI protein and
5 activated protein C such that an activated protein C plasma level of about 2 ng/ml to about 300 ng/ml is achieved.

12. The method of Claim 11 wherein the activated protein C is administered in a bolus injection.

10 13. The method of Claim 11 wherein the activated protein C is administered by continuous infusion for about 1 to about 240 hours.

15 14. The method of Claim 11 wherein the activated protein C is administered first as a bolus then as a continuous infusion.

20 15. The method of Claim 14 wherein one third of the activated protein C required to achieve activated protein C plasma levels in the range of about 2 ng/ml to about 300 ng/ml is administered in a bolus injection followed by continuous infusion of the remaining two thirds of the activated protein C.

1022011 E5E35560